AcuraBio recapitalized by Ampersand Capital Partners

Aug. 2022

Client: AcuraBio is an Australia-based contract development and manufacturing organization (CDMO) that provides specialized drug development and biomanufacturing services to the pharmaceutical, biotechnology, and veterinary industries worldwide

Role: Edgemont Partners acted as financial advisor to AcuraBio for its recapitalization by Ampersand Capital Partners

Location: Brisbane, Australia

Sector: Pharmaceutical Services

Lead Banker: Andrew Karlin

View Press Release

recapitalized by

Get In Touch